SG11201603244VA - Production of t cell retargeting hetero-dimeric immunoglobulins - Google Patents

Production of t cell retargeting hetero-dimeric immunoglobulins

Info

Publication number
SG11201603244VA
SG11201603244VA SG11201603244VA SG11201603244VA SG11201603244VA SG 11201603244V A SG11201603244V A SG 11201603244VA SG 11201603244V A SG11201603244V A SG 11201603244VA SG 11201603244V A SG11201603244V A SG 11201603244VA SG 11201603244V A SG11201603244V A SG 11201603244VA
Authority
SG
Singapore
Prior art keywords
production
dimeric immunoglobulins
cell retargeting
hetero
retargeting hetero
Prior art date
Application number
SG11201603244VA
Other languages
English (en)
Inventor
Stanislas Blein
Romain Ollier
Samuel Hou
Darko Skegro
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49513866&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201603244V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of SG11201603244VA publication Critical patent/SG11201603244VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201603244VA 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins SG11201603244VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13191386 2013-11-04
PCT/EP2014/073738 WO2015063339A1 (en) 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins

Publications (1)

Publication Number Publication Date
SG11201603244VA true SG11201603244VA (en) 2016-05-30

Family

ID=49513866

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201603244VA SG11201603244VA (en) 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins
SG10201909806S SG10201909806SA (en) 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201909806S SG10201909806SA (en) 2013-11-04 2014-11-04 Production of t cell retargeting hetero-dimeric immunoglobulins

Country Status (22)

Country Link
US (7) US9493563B2 (enExample)
EP (3) EP3066133A1 (enExample)
JP (3) JP2016538275A (enExample)
KR (2) KR20160090308A (enExample)
CN (3) CN105873953A (enExample)
AP (1) AP2016009222A0 (enExample)
AU (3) AU2014343636A1 (enExample)
BR (2) BR112016009919A2 (enExample)
CA (2) CA2929256C (enExample)
CL (1) CL2016001068A1 (enExample)
EA (1) EA036577B1 (enExample)
HK (1) HK1244013A1 (enExample)
IL (2) IL245381B (enExample)
MA (1) MA40889A (enExample)
MX (1) MX375389B (enExample)
MY (1) MY176522A (enExample)
NZ (1) NZ720161A (enExample)
PE (1) PE20160724A1 (enExample)
PH (1) PH12016500823A1 (enExample)
SG (2) SG11201603244VA (enExample)
WO (2) WO2015063339A1 (enExample)
ZA (1) ZA201603433B (enExample)

Families Citing this family (169)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2603408C (en) 2005-03-31 2018-08-21 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
ES2654040T3 (es) 2006-03-31 2018-02-12 Chugai Seiyaku Kabushiki Kaisha Método de modificación de anticuerpos para la purificación de anticuerpos biespecíficos
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX336725B (es) 2007-09-26 2016-01-28 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
RU2526512C2 (ru) 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
CN105585630B (zh) 2010-07-29 2020-09-15 Xencor公司 具有修改的等电点的抗体
EP3318633A1 (en) 2010-11-17 2018-05-09 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
SG190726A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Cytotoxicity-inducing therapeutic agent
BR112013023918A2 (pt) * 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
CN104822704B (zh) * 2012-06-14 2020-02-14 医疗生物科学有限公司 针对分化簇3(cd3)的人源化的抗体
IN2015MN00139A (enExample) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
KR102391731B1 (ko) 2013-01-14 2022-04-27 젠코어 인코포레이티드 신규한 이형이량체 단백질
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
US10351626B2 (en) 2013-03-14 2019-07-16 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
WO2015046467A1 (ja) 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CN105873953A (zh) * 2013-11-04 2016-08-17 格兰马克药品股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
JP6449295B2 (ja) 2013-12-17 2019-01-09 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体および使用方法
TN2017000532A1 (en) * 2014-03-28 2019-04-12 Xencor Inc Bispecific antibodies that bind to cd38 and cd3.
WO2015156268A1 (ja) 2014-04-07 2015-10-15 中外製薬株式会社 免疫活性化抗原結合分子
CN106459954A (zh) 2014-05-13 2017-02-22 中外制药株式会社 用于具有免疫抑制功能的细胞的t细胞重定向的抗原结合分子
AU2015314744A1 (en) 2014-09-12 2017-03-02 Genentech, Inc. Anti-CLL-1 antibodies and immunoconjugates
US11773166B2 (en) 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
MA40894A (fr) * 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN107406512A (zh) * 2014-11-26 2017-11-28 Xencor公司 结合cd3和cd38的异二聚体抗体
BR112017011092A2 (pt) 2014-11-26 2017-12-26 Xencor Inc anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
US10428155B2 (en) 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
SG11201706774WA (en) * 2015-02-27 2017-09-28 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
CN115109158A (zh) 2015-05-07 2022-09-27 阿吉纳斯公司 抗ox40抗体及其使用方法
PT3310814T (pt) 2015-06-16 2023-10-02 H Hoffnabb La Roche Ag Anticorpos humanizados e de afinidade amadurecida para fcrh5 e métodos de utilização
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
JP2018526972A (ja) 2015-06-16 2018-09-20 ジェネンテック， インコーポレイテッド 抗ｃｄ３抗体及び使用方法
MY180297A (en) 2015-06-24 2020-11-27 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
CA2990177A1 (en) 2015-06-25 2016-12-29 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN116675776A (zh) 2015-10-25 2023-09-01 赛诺菲 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白
JP6925278B2 (ja) * 2015-11-18 2021-08-25 中外製薬株式会社 液性免疫応答の増強方法
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
CA3007233A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
CN110698560B (zh) * 2015-12-24 2021-11-26 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE EFFICIENCY OF CLEANING POLYPEPTIDE WITH FC REGION
AU2017213886B2 (en) 2016-02-04 2024-03-07 The California Institute For Biomedical Research Humanized anti-CD3 antibodies, conjugates and uses thereof
EP3433273B1 (en) 2016-03-25 2021-12-29 Biomunex Pharmaceuticals Binding molecules to cd38 and pd-l1
CN109476732B (zh) 2016-04-13 2024-03-22 赛诺菲 三特异性和/或三价结合蛋白
MY192090A (en) 2016-04-13 2022-07-26 Sanofi Sa Trispecific and/or trivalent binding proteins
AU2017255970B2 (en) 2016-04-28 2024-06-27 Biomunex Pharmaceuticals Bispecific antibodies targeting EGFR and HER2
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
EP3468586B1 (en) 2016-06-14 2024-08-07 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
US20200283534A1 (en) 2016-06-24 2020-09-10 iCell Gene Therapeuticics LLC CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
WO2018005706A1 (en) 2016-06-28 2018-01-04 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
KR102435801B1 (ko) * 2016-07-22 2022-08-25 암젠 인크 Fc-함유 단백질의 정제 방법
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20240044520A (ko) 2016-09-14 2024-04-04 테네오원, 인코포레이티드 Cd3 결합 항체
KR20190065318A (ko) 2016-09-23 2019-06-11 메뤼스 엔.페. 세포에 의해 발현되는 생물학적 활성을 조절하는 결합 분자
CN106632681B (zh) 2016-10-11 2017-11-14 北京东方百泰生物科技有限公司 抗egfr和抗cd3双特异抗体及其应用
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EP4215548A1 (en) 2016-12-21 2023-07-26 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
CN106749678A (zh) * 2017-01-09 2017-05-31 北京普瑞金科技有限公司 Her2 car重组慢病毒载体及其构建方法与应用
SG11201908825TA (en) 2017-03-27 2019-10-30 Biomunex Pharmaceuticals Stable multispecific antibodies
SG11201909498XA (en) * 2017-04-24 2019-11-28 Glenmark Pharmaceuticals Sa T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
WO2018224441A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
JP7710827B2 (ja) * 2017-06-05 2025-07-22 ヤンセン バイオテツク，インコーポレーテツド 非対称なｃｈ２－ｃｈ３領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
KR102651965B1 (ko) * 2017-06-05 2024-03-28 누맙 세러퓨틱스 아게 신규 항 cd3 항체
CN118146370A (zh) 2017-06-20 2024-06-07 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
CN117866097A (zh) 2017-06-20 2024-04-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
CN111247242B (zh) 2017-06-21 2024-07-19 美商生物细胞基因治疗有限公司 嵌合抗原受体(CARs)、组合物及其使用方法
EP3645122A1 (en) 2017-06-30 2020-05-06 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
WO2019034580A1 (en) 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
CA3075399A1 (en) * 2017-09-13 2019-03-21 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
JP7036909B2 (ja) * 2017-10-10 2022-03-15 サノフイ 抗ｃｄ３８抗体および使用方法
IL274265B1 (en) 2017-11-01 2025-09-01 Chugai Pharmaceutical Co Ltd Variant and isoform of an antibody with attenuated biological activity
WO2019094637A1 (en) 2017-11-08 2019-05-16 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-pd-1 sequences
KR102782136B1 (ko) 2017-11-08 2025-03-18 쿄와 기린 가부시키가이샤 CD40과 EpCAM에 결합하는 이중특이적 항체
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
WO2019133761A1 (en) * 2017-12-27 2019-07-04 Teneobio, Inc. Cd3-delta/epsilon heterodimer specific antibodies
WO2019143636A1 (en) * 2018-01-16 2019-07-25 Lakepharma, Inc. Bispecific antibody that binds cd3 and another target
MA51793A (fr) 2018-02-08 2020-12-16 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation
CN120399075A (zh) * 2018-03-14 2025-08-01 诺维莫尼公司 抗-CD3ε抗体及其应用方法
CN110305217B (zh) 2018-03-27 2022-03-29 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
EP3773911A2 (en) 2018-04-04 2021-02-17 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
AU2019256529A1 (en) 2018-04-18 2020-11-26 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
WO2019204665A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
FI3797121T3 (fi) * 2018-05-23 2024-08-22 Pfizer Cd3:lle spesifisiä vasta-aineita ja niiden käyttöjä
WO2019224385A2 (en) * 2018-05-24 2019-11-28 Glenmark Pharmaceuticals S.A. Combined bispecific antibody and immuno-oncology therapies
WO2019244107A1 (en) * 2018-06-21 2019-12-26 Daiichi Sankyo Company, Limited Compositions including cd3 antigen binding fragments and uses thereof
MX2021001915A (es) 2018-08-17 2021-05-31 Regeneron Pharma Metodo y sistema de cromatografia para determinar la cantidad y pureza de una proteina multimerica.
EP3620785A1 (en) * 2018-09-07 2020-03-11 Ares Trading S.A. Electrophoresis-based characterization of fc fusion proteins
CA3113756A1 (en) * 2018-09-25 2020-04-02 Ichnos Sciences S.A. Antibody quantification in biological samples
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
MX2021004147A (es) 2018-10-09 2021-09-08 Sanofi Sa Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
US20210388106A1 (en) * 2018-10-26 2021-12-16 Teneobio, Inc. Heavy chain antibodies binding to cd38
WO2020112970A1 (en) * 2018-11-30 2020-06-04 The Trustees Of The University Of Pennsylvania Bw6 specific car designed to protect transplanted tissue from rejection
CN113260379B (zh) 2018-12-21 2022-09-02 浙江时迈药业有限公司 蛋白酶可切割的双特异性抗体及其用途
SG11202109406TA (en) 2019-03-01 2021-09-29 Xencor Inc Heterodimeric antibodies that bind enpp3 and cd3
KR20210141555A (ko) 2019-03-14 2021-11-23 제넨테크, 인크. Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료
CN114008079A (zh) * 2019-03-20 2022-02-01 贾夫林肿瘤学公司 抗adam12抗体和嵌合抗原受体以及包含其的组合物和方法
PE20220142A1 (es) 2019-04-05 2022-01-27 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
KR102239781B1 (ko) 2019-04-08 2021-04-13 주식회사 녹십자 Gpnmb 및 cd3에 특이적으로 결합하는 이중특이적 항체 및 이의 용도
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
MX2021014193A (es) * 2019-05-23 2022-01-06 Velosbio Inc Moleculas de enlace biespecificas anti-ror1/anti-cd3.
EP3983438A1 (en) 2019-06-14 2022-04-20 TeneoBio, Inc. Multispecific heavy chain antibodies binding to cd22 and cd3
JP2022538008A (ja) * 2019-06-26 2022-08-31 ザ・ジョンズ・ホプキンス・ユニバーシティ 免疫エフェクター細胞をターゲット化して増殖させるための方法及び材料
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
EP3999115A4 (en) * 2019-07-12 2023-11-22 LipUm AB NEW BSSL ANTIBODIES
EP3791931A1 (en) * 2019-09-13 2021-03-17 Ichnos Sciences SA Bispecific antibodies for the treatment of solid tumors
US20220348661A1 (en) 2019-09-30 2022-11-03 Harbour Biomed (suzhou) Co., Ltd. Cd3-targeting antibody, bispecific antibody and use thereof
CN112876563B (zh) * 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
MX2022006972A (es) * 2019-12-26 2022-08-04 Abl Bio Inc Metodo para la purificacion de peptido biologicamente activo utilizando cromatografia de afinidad con proteina a.
CA3165045A1 (en) * 2020-01-23 2021-07-29 Adagene Ag Heterodimeric proteins with fc mutations
TWI888487B (zh) 2020-02-14 2025-07-01 日商協和麒麟股份有限公司 與ｃｄ３結合之雙特異性抗體
EP4106880A4 (en) * 2020-02-17 2024-07-03 Board of Regents, The University of Texas System HUMAN 4-1BB AGONIST ANTIBODIES AND METHODS OF USE THEREOF
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CA3218661A1 (en) 2020-04-04 2022-11-17 David Campbell Compositions and methods related to tumor activated antibodies targeting egfr and effector cell antigens
WO2021222595A2 (en) * 2020-04-30 2021-11-04 Virtuoso Binco, Inc. Multispecific antibodies targeting cd38 and epcam and uses thereof
IL297412A (en) 2020-05-04 2022-12-01 Immunorizon Ltd Precursor tri-specific antibody constructs and methods of use thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN115996704A (zh) * 2020-06-12 2023-04-21 伊克诺斯科学公司 抗体制剂稀释剂
TWI806088B (zh) 2020-06-30 2023-06-21 大陸商和鉑醫藥（上海）有限責任公司 具有H2L2與HCAb結構的結合蛋白
CN120040592A (zh) * 2020-07-31 2025-05-27 百奥泰生物制药股份有限公司 Cd47抗体及其应用
US11197910B1 (en) 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
US11124568B1 (en) * 2020-08-19 2021-09-21 Vitruviae LLC CD3/CD25 antibodies for neuro-immune diseases
KR20230054456A (ko) 2020-08-25 2023-04-24 길리애드 사이언시즈, 인코포레이티드 Hiv를 표적으로 하는 다중특이적 항원 결합 분자 및 이의 사용 방법
US20230406955A1 (en) * 2020-10-22 2023-12-21 Janux Therapeutics, Inc. Antibodies targeting her2 and cd3 and uses thereof
AU2021374592A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EP4240766A2 (en) 2020-11-04 2023-09-13 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
WO2022148736A1 (en) * 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
EP4305067A1 (en) 2021-03-09 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
JP2024509274A (ja) 2021-03-10 2024-02-29 ゼンコア インコーポレイテッド Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
MX2023011267A (es) 2021-03-24 2023-12-14 Janssen Biotech Inc Anticuerpo triespecífico dirigido a cd79b, cd20, y cd3.
CN114763387B (zh) * 2021-04-15 2024-06-25 北京大学深圳研究生院 一种基于结构优化蛋白活性的三特异性抗体制备方法
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
JP2024530166A (ja) * 2021-08-04 2024-08-16 アブプロ コーポレーション Ｃｄ３標的化抗体及びそれらの使用
EP4405392A1 (en) * 2021-09-24 2024-07-31 Janssen Biotech, Inc. Proteins comprising cd20 binding domains, and uses thereof
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
JP2025519477A (ja) 2022-06-07 2025-06-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔ細胞活性を調節するための多重特異性分子及びその使用
WO2024071008A1 (ja) * 2022-09-26 2024-04-04 愛知県 抗原分子の単離方法
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
AU2023411854A1 (en) * 2022-12-19 2025-07-10 Harbour Biomed (Shanghai) Co., Ltd. “kappa/lambda” fab-fab series-connection multi-specific binding protein, preparation thereof, and use thereof
EP4665385A2 (en) 2023-02-17 2025-12-24 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
TW202532440A (zh) 2023-10-19 2025-08-16 美商建南德克公司 用於治療ＨＥＲ２陽性癌症的ＩＬ１５／ＩＬ１５Ｒα異二聚體ＦＣ融合蛋白及ＨＥＲ２ｘＣＤ３雙特異性抗體之組合

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
EP0547065B1 (en) 1990-06-29 2001-08-29 Large Scale Biology Corporation Melanin production by transformed microorganisms
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US6329509B1 (en) 1991-08-14 2001-12-11 Genentech, Inc. Anti-IgE antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
ATE218143T1 (de) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
AU2002310222A1 (en) 2001-05-31 2002-12-09 Chiron Corporation P-cadherin as a target for anti-cancer therapy
BRPI0507489A (pt) 2004-02-06 2007-07-10 Morphosys Ag anticorpos humanos de anti-cd38 e para os seus usos
IL316252A (en) 2005-03-23 2024-12-01 Genmab As Antibodies against cd38 for treatment of multiple myeloma
CA2625440C (en) * 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
CN104497143B (zh) 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
US20100150918A1 (en) 2007-04-03 2010-06-17 Micromet Ag Cross-species-specific binding domain
ES2589852T3 (es) 2008-09-17 2016-11-16 Xencor Inc. Anticuerpo específico para IgE
MX2011006870A (es) * 2008-12-23 2011-07-19 Genentech Inc Variantes de inmunoglobulina con union alterada a proteina a.
CN102421800A (zh) 2009-02-23 2012-04-18 格兰马克药品股份有限公司 结合cd19的人源化抗体及其用途
MA33198B1 (fr) 2009-03-20 2012-04-02 Genentech Inc Anticorps anti-her di-spécifiques
MY199658A (en) 2009-06-26 2023-11-14 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
KR102103093B1 (ko) * 2009-12-25 2020-04-21 추가이 세이야쿠 가부시키가이샤 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법
JP6040148B2 (ja) 2010-04-20 2016-12-07 ゲンマブ エー／エス ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
PT2580243T (pt) 2010-06-09 2020-01-22 Genmab As Anticorpos contra cd38 humana
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
BR112013023918A2 (pt) * 2011-03-25 2016-12-13 Glenmark Pharmaceuticals Sa imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para produzir uma imunoglobulina hetero-dimérica ou fragmento hetero-dimérico da mesma, método para construir uma interface proteína-proteína de um domínio de uma proteína de múltiplos domínios e uso de um domínio doador de um primeiro e de um segundo membro de uma super-família de imunoglobulina de ocorrência natural
EP2694552B1 (en) 2011-04-07 2017-10-11 Amgen Inc. Novel egfr binding proteins
US20140170149A1 (en) 2011-04-20 2014-06-19 Genmab A/S Bispecific antibodies against her2 and cd3
US8846042B2 (en) 2011-05-16 2014-09-30 Fabion Pharmaceuticals, Inc. Multi-specific FAB fusion proteins and methods of use
PH12014500089A1 (en) 2011-07-11 2014-02-17 Ichnos Sciences SA Antibodies that bind to ox40 and their uses
PL2771364T3 (pl) 2011-10-27 2020-01-31 Genmab A/S Wytwarzanie heterodimerycznych białek
IN2015MN00139A (enExample) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
AP2015008605A0 (en) * 2013-01-02 2015-07-31 Glenmark Pharmaceuticals Sa Antibodies that bind to tl1a and their uses
US10351626B2 (en) * 2013-03-14 2019-07-16 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
EP2951203B1 (en) * 2013-03-15 2019-05-22 Xencor, Inc. Heterodimeric proteins
CN105431320B (zh) 2013-08-02 2018-07-13 施耐德电气美国股份有限公司 电动交通工具充电站手柄输入
CN105873953A (zh) 2013-11-04 2016-08-17 格兰马克药品股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
EP2982693A1 (en) 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
MA40894A (fr) 2014-11-04 2017-09-12 Glenmark Pharmaceuticals Sa Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
US11773166B2 (en) * 2014-11-04 2023-10-03 Ichnos Sciences SA CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US20200347143A1 (en) * 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
SG11201909498XA (en) * 2017-04-24 2019-11-28 Glenmark Pharmaceuticals Sa T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
CN115996704A (zh) * 2020-06-12 2023-04-21 伊克诺斯科学公司 抗体制剂稀释剂

Also Published As

Publication number Publication date
AU2019257534A1 (en) 2019-11-28
CN105873953A (zh) 2016-08-17
JP2017536412A (ja) 2017-12-07
EP3215540A1 (en) 2017-09-13
WO2016071004A1 (en) 2016-05-12
AU2019257534B2 (en) 2021-12-09
NZ720161A (en) 2022-07-29
AU2014343636A1 (en) 2016-06-02
SG10201909806SA (en) 2019-11-28
BR112017009264A2 (pt) 2018-01-30
US11891454B2 (en) 2024-02-06
PH12016500823A1 (en) 2016-06-13
EA036577B1 (ru) 2020-11-25
EA201690803A1 (ru) 2016-09-30
CL2016001068A1 (es) 2016-11-18
BR112016009919A2 (pt) 2017-12-05
CN110627907B (zh) 2024-03-29
MA40889A (fr) 2017-09-12
US20170145115A1 (en) 2017-05-25
MY176522A (en) 2020-08-13
MX2016005781A (es) 2016-07-18
US20200102403A1 (en) 2020-04-02
US20180112011A1 (en) 2018-04-26
MX375389B (es) 2025-03-06
US20220213227A1 (en) 2022-07-07
AP2016009222A0 (en) 2016-05-31
JP6994942B2 (ja) 2022-02-04
HK1244013A1 (zh) 2018-07-27
US9493563B2 (en) 2016-11-15
IL251850A0 (en) 2017-06-29
EP3066133A1 (en) 2016-09-14
JP2020023516A (ja) 2020-02-13
KR20160090308A (ko) 2016-07-29
CN107207595A (zh) 2017-09-26
US11851502B2 (en) 2023-12-26
JP7068251B2 (ja) 2022-05-16
US20150133640A1 (en) 2015-05-14
KR20170092562A (ko) 2017-08-11
EP3176185A1 (en) 2017-06-07
AU2015342169A1 (en) 2017-06-08
CA2966124A1 (en) 2016-05-12
US20210171661A1 (en) 2021-06-10
IL245381B (en) 2021-09-30
JP2016538275A (ja) 2016-12-08
PE20160724A1 (es) 2016-08-04
IL245381A0 (en) 2016-06-30
ZA201603433B (en) 2019-03-27
WO2015063339A1 (en) 2015-05-07
CA2929256A1 (en) 2015-05-07
CA2966124C (en) 2023-01-03
CN110627907A (zh) 2019-12-31
US20180355064A1 (en) 2018-12-13
CA2929256C (en) 2022-04-26

Similar Documents

Publication Publication Date Title
ZA201603433B (en) Production of t cell retargeting hetero-dimeric immunoglobulins
GB201401248D0 (en) Method of manufacture
GB2511914B (en) Object production
PL3006568T3 (pl) Sposób wytwarzania tagatozy
PL3049439T3 (pl) Bispecyficzne nanociała
GB201517764D0 (en) Simulation of production systems
ZA201509334B (en) Improved process for production of monoclonal antibodies
SG11201504608SA (en) Production of para-xylene
IL245265A0 (en) Antibodies specific for fcrn
PL3041945T3 (pl) Wytwarzanie galakto-oligosacharydów
GB201414400D0 (en) Object production
EP2952895A4 (en) PROCESS FOR PRODUCING A MARKED ANTIBODY
GB201305231D0 (en) Method of Manufacture
HUE073098T2 (hu) Madárembrió sejtek termelése
GB201306810D0 (en) Methods of cell separation
GB201707235D0 (en) Production of butanol
IL244533A0 (en) Improved ammunition production
IL241475A0 (en) method for synthesis
GB201306986D0 (en) Can production process
GB201304818D0 (en) Production of bioethanol
GB201303595D0 (en) Production of butanol
GB201311291D0 (en) Method of manufacture
GB201301262D0 (en) Method of manufacture
GB2529100B (en) Improved ammunition production
SG10201701021XA (en) Method of synthesis